Baxalta Now Part Of Shire

This study tested a new medicine called BAX 930 in 52 people born with severe TTP, a rare blood disorder that causes dangerous clots and bleeding. The medicine replaces a missing enzyme to prevent or treat sudden flare-ups. Participants received either BAX 930 or standard treatme…

This study tested a new medicine called vonicog alfa (rVWF) to help control bleeding in children under 18 with severe von Willebrand disease, a blood disorder that causes easy bruising and heavy bleeding. The treatment was given with or without another drug (ADVATE) for 12-18 mon…

This study tested a medication called rVWF (vonicog alfa) in 38 children and adults with severe von Willebrand disease, a bleeding disorder. The goal was to see how well it prevents spontaneous bleeding over 12 months. Participants received rVWF for up to 3 years, and researchers…

This study tested a gene therapy called BAX 888 in 4 adult men with severe hemophilia A, a bleeding disorder. Participants received a single intravenous infusion of the therapy to help their bodies produce a missing clotting protein. The main goals were to check for side effects …